3D-Printing is, without argument, a disruptive technology in the healthcare sector.
3D-printing startups are already making healthcare products and processes more accessible and customizable.
Although large pharmaceutical companies have yet to feel the change in the market, they should invest in the 3D-printing future.
Artem Gassan, cofounder and CEO of Whale Path, as well as a Graduate of the Silicon Valley Founder Institute, has outlined the effect 3D-printing will have on Big Pharma in the Huffington Post article, “The Big Ideas 3D-Printing Brings to Big Pharma”.
The ability to 3D-print pharmaceuticals and customized medications from any location may sound like a recipe for disaster and seem like a large threat to Big Pharma revenue.
However, a lack of pharmaceutical knowledge will keep consumers dependent on both large and small pharmaceutical companies despite the technological advance.